For this reason, it seems necessary to perform a longer follow-up to further study the relationships between skin ADRs and these key evaluation indicators of cancer treatment (e.g. RR & OS) in NSCLC patients under EGFR-TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.